cabozantinib,pembrolizumab
exelixis,merck
['head and neck', 'hncsm', 'cabozantinib', 'pembrolizumab']
#asco22 | june 3 | oral abstract session | head and neck cancer
"a phase ii trial of pembrolizumab and cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma"
presenter: nabil saba, md
#hncsm 
As Georgia's NCI Comprehensive Cancer Center, we are at the forefront of cancer research, innovation, and discovery. Request patient appointment: (888) 946-7447